The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $412,125 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The Research Foundation For The State University Of New York to study the impact of prenatal alcohol and methadone exposure on the regulation of dopamine signaling and synaptic plasticity in the basolateral amygdala. The two-year project aims to determine how the combined exposure to prenatal alcohol and methadone alters social and non-social...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
This federal Project Grant award, valued at $499,987.00 and provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), supports the development of a High Throughput Alcohol Screening Platform (HT-ASP) incorporating cortical organoids. The objective is to adapt an existing microphysiological system (MPS) platform to create a robust, automated platform capable of maturing, maintaining, and assaying over 100 brain organoids in...
This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
The University of Pittsburgh is receiving a $437,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant aims to provide proof-of-concept evidence that retinoic acid (RA) can attenuate cholinergic deficits and white matter connectivity impairments after traumatic brain injury (TBI). The two-year project will: 1) determine if RA treatment...
Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
This federal Project Grant award of $361,975.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support the development of chemical probes to visualize and manipulate astrocytes, the brain's support cells, and their interactions with neurons. The funded research aims to expand on the awardee's preliminary work in designing chemical tags that can...
This federal Project Grant award of $126,442 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the effects of delta-9-tetrahydrocannabinol (THC) exposure during brain development in a ferret animal model. The key products or services to be delivered through this funding include: Using RNA-scope technology to determine if there is a decrease in cannabinoid receptor type-1 (CB1R) expression in...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides funding of $725,192 to The Leland Stanford Junior University to conduct research on using the drug vinpocetine to treat cognitive deficits caused by fetal alcohol exposure. The key objectives of this research project are to: 1) characterize the dose-response relationship of vinpocetine in animal models of fetal alcohol spectrum...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $235,750 Project Grant (CFDA 93.273 - Alcohol Research Programs) to Rhode Island Hospital to study the detection and monitoring of alcohol-related white matter brain pathology. The project aims to leverage the hospital's existing bank of human alcohol use disorder (AUD) and control serum samples to characterize the effects of ethanol and different treatments on the expression of oligodendrocyte/myelin proteins,...